Lung Cancer

Clinical Trial Evaluates IL-2 and (beta)-IFN in Lung Cancer

Published in Cancer Weekly, November 15th, 1999

Researchers from the United States conducted a randomized Phase II study of interleukin-2 (IL-2) with and without beta-interferon ((beta)-IFN) for patients with advanced non-small cell lung cancer.

"IL-2 and (beta)-IFN are biologic agents with antitumor activity observed in preclinical models," stated W.J. Tester and colleagues from the Albert Einstein Cancer Center, Pennsylvania. "Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates."

Tester et al. published the results of their study in the journal Lung Cancer ("A Randomized Phase II Study of Interleukin-2...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry